Drug benefits are the most significant cost component in most employer-sponsored health benefits plans. Drug costs range between 40% and 70% of an organization’s total health benefits costs, and they are set to rise.
Morneau Shepell's 30th annual Compensation - Trends and Projections survey results found that pension plan sponsors intend to get more serious about pension and benefits costs next year.
In honour of Benefits Canada’s 35th anniversary, we took the opportunity to go back to the source to explore why employers offer employee benefits programs. Our research looks at the past, present and future of employee benefits—and shows how much senior business leaders value them. Cost concerns and the desire to more directly connect investment […]
Small business owners in Nova Scotia will likely be saving money on their prescription drug costs this year.
Finding the right benefits consultant is as important a task as selecting your firm’s lawyer or accountant. These professionals play an integral role in the direction your company takes and help to ensure the long-term sustainability of your most precious resource: your people.
It may seem too good to be true, but it looks like increases in health benefits plan costs are slowing.
Perhaps not surprisingly, cost is the main driver for senior decision-makers when it comes to their pension and benefits plans.
Canadian employers may intuitively understand the benefits of investing in prevention and health promotion programs for their employees, but they’re still struggling to demonstrate a clear, positive return on investment (ROI) for such programs.
The lure of better rates, better service, streamlined administration, faster claims reimbursement and a more client focused service platform are the focal points used by carriers to attract employee benefits plan business.
While biologic drugs can represent a significant percentage of a plan’s drug costs, a Green Shield report says they are not the only thing driving up costs. Of course, plan sponsors need to actively manage biologics as use continues to grow, but they need to look for other places to also control drugs costs.